HITV Lab

Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Home HITV Cancer Therapy How HITV Works Treatment Protocol Chart

Tuesday17 October 2017

Treatment Protocol Chart

HITV Treatment Protocol Chart

HITV Treatment Protocol Chart

Prior to treatment, the extent of disease and the location of metastases are established by PET CT ( Positron Emission Tomography - Computed Tomography ).

 

The patient undergoes leukapheresis to obtain monocytes for differentiation into iDC and a monocyte depleted T-cell enriched population for preparation of activated T-cells ( AT ).

 

After preparation of these reagents, a portion of the iDC is combined with lymphocyte conditioned media, a multi-cytokine based adjuvant ( LCM ), and KLH. This cell mixture is equally divided based on the number of sites to be injected.

 

AT shall be infused the following day. Approximately 5 days later, the injected tumor sites received Intensity-Modulated Radiotherapy ( IMRT ) in divided doses.

 

Three to five days following the last dose of radiation, the tumor sites are again injected with iDC suspended in LCM ( without KLH ) and AT infused the next day. Blood samples are obtained prior to protocol initiation and periodically thereafter to monitor serum levels of tumor markers and the development of anti-KLH antibodies.

 

The PET-CT exam is repeated 6 weeks after the last treatment and periodically thereafter. The treatment cycle will be repeated for patients who developed lesions at new sites.

HITV Lab

HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks